the food and drug administration (fda) and bristol-myers squibb have announced revisions to the labeling of warfarin (coumadin) and a new medication guide for patients. the drug label has been reorganized to highlight safety information. this is a move intended to help reduce the risk of errors with this anticoagulant. which is considered difficult to manage. fda also requires that the new medication guide be provided with each warfarin prescription.